Page last updated: 2024-08-23

idarubicin and Carcinoma, Ductal, Breast

idarubicin has been researched along with Carcinoma, Ductal, Breast in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barba, G; Cicconi, L; Divona, M; Falini, B; Hasan, SK; Lo-Coco, F; Mecucci, C; Metzler, M; Ottone, T	1
Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z	1
Arnoldi, E; Barni, S; Bolognesi, A; Intini, C; Tabiadon, D; Zaniboni, A	1

Trials

1 trial(s) available for idarubicin and Carcinoma, Ductal, Breast

Article	Year
Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. Anti-cancer drugs, 1998, Volume: 9, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Female; Humans; Idarubicin; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors	1998

Article

Year

Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients.

Anti-cancer drugs, 1998, Volume: 9, Issue:4

Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Female; Humans; Idarubicin; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Time Factors

1998

Other Studies

2 other study(ies) available for idarubicin and Carcinoma, Ductal, Breast

Article	Year
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23). Genes, chromosomes & cancer, 2014, Volume: 53, Issue:3 Topics: Antibiotics, Antineoplastic; Base Sequence; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Epirubicin; Female; Genetic Loci; Humans; Idarubicin; Leukemia, Biphenotypic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Molecular Sequence Data; Multigene Family; Topoisomerase Inhibitors; Translocation, Genetic	2014
t(8;16) AML developed subsequent to breast cancer therapy. Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles	2006

Article

Year

Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23).

Genes, chromosomes & cancer, 2014, Volume: 53, Issue:3

Topics: Antibiotics, Antineoplastic; Base Sequence; Breast Neoplasms; Carcinoma, Ductal, Breast; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Epirubicin; Female; Genetic Loci; Humans; Idarubicin; Leukemia, Biphenotypic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Molecular Sequence Data; Multigene Family; Topoisomerase Inhibitors; Translocation, Genetic

2014

t(8;16) AML developed subsequent to breast cancer therapy.

Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles

2006